New Jersey-Based Pharmaceutical Contract Drug Manufacturer Selects ValGenesis VLMS to Digitize Validation Process


SAN FRANCISCO, January 29, 2019 /PRNewswire/ — ValGenesis, Inc., a market leader in enterprise validation lifecycle management (VLMS) solutions, today announced that a New JerseyOne of ValGenesis’ leading pharmaceutical drug contract manufacturers chose ValGenesis’ 100% paperless VLMS to manage their validation lifecycle process.

Serving the North American market, this trusted manufacturer is focused on acquiring, developing, manufacturing and marketing high quality niche generic prescription pharmaceutical products in a variety of dosage forms and therapeutic categories to meet the specific patient needs. The Company offers products in various formulations, such as suspensions, emulsions/foams, topical gels, creams and suppositories. With the expertise, equipment and state-of-the-art infrastructure to ensure successful contract development and manufacturing of a wide range of sterile and controlled environment products, including Class IV AEDs, the company also develops medical devices , over-the-counter drugs and other related products.

Realizing that traditional paper-based validation processes were both costly and inefficient, the company decided it was time to consider a paperless solution. They conducted a detailed evaluation of several solutions and selected ValGenesis Enterprise VLMS, a paperless electronic solution that meets the company’s validation lifecycle needs well. With ValGenesis Enterprise VLMS, the company will significantly reduce validation cycle time, achieve a higher level of data integrity, improve regulatory compliance, and gain a holistic view of real-time validation statuses across its regulated systems, thereby improving the quality and speed of the Complete procedure.

“ValGenesis is delighted to have been selected as the right tool to help automate its IT system validation process,” says Narayan RajVice President of ValGenesis Inc. “Our VLMS is an ideal solution for companies like this, who want to reduce overall validation time while realizing significant cost savings. Now these companies can focus on what they they do best, to be a trusted subcontractor that delivers pharmaceutical quality drugs.”

About ValGenesis
ValGenesis, Inc. is the creator of an innovative software platform that serves as the foundation for managing compliance-based validation activities in life science companies. ValGenesis, Inc. is the provider of the first enterprise application that manages the enterprise validation lifecycle process. As the first completely paperless solution for 100% electronic management of validation execution and approval, ValGenesis has been selected by an industry peer review committee to receive the award for innovative new technology from the Parenteral Drug Association (PDA) in 2005. The solution is also fully compliant with US standards. FDA 21 CFR Part 11 and Appendix 11 requirements.

For more information, visit

Further information :
Althea D’Sylva, ValGenesis Communications, +1 510-445-0505 Ex. 1026, [email protected]

SOURCEValGenesis Inc.

Related links


Comments are closed.